

Help contribute to **CAA** **RESEARCH**

**Introducing the cAPPricorn-1 clinical trial for people
living with cerebral amyloid angiopathy (CAA)**

cAPPricorn-1 is researching an investigational medication called mivelsiran to see if it could be safe and effective.

Participating in this trial may be an opportunity to contribute to CAA research.

WHO CAN JOIN?

Participants with sporadic CAA:

- 50 years of age or older
- Have received a diagnosis of CAA from their doctor

Participants with Dutch-type CAA:

- 30 years of age or older
- Have a known gene mutation for Dutch-type CAA

Additional criteria will be assessed by the study team to determine your eligibility.

For more information, visit Cappricorn1.com or reach out to the study team:

UCLA Neurology
Study Coordinator: Isaias Gomez, MS
Phone: (310) 825-1863
Site Investigator: Kyle Kern, MD



cAPPricorn-1